指南与共识前列腺癌

指南之指南:前列腺癌局灶治疗,是时候达成共识了吗?

Guidelines of guidelines: focal therapy for prostate cancer, is it time for consensus?
指南 / 共识 · BJU Int · 2022-09-27

本文总结并讨论了国际指南、立场声明和共识声明中关于前列腺癌局灶治疗(FT)的内容。结果显示缺乏FT的长期随机数据,国际泌尿外科指南强调需要更多高质量临床试验并提供可靠的肿瘤学和毒性结局,共识和立场声明异质性大。结论认为全球公认的FT规划、技术和随访指南仍未确定,需要设计良好、长期随访且具有可靠临床和毒性终点的研究来改善对FT的理解并制定统一指南。

要点

  • 缺乏前列腺癌局灶治疗的长期随机数据。
  • 国际泌尿外科指南强调需要更多高质量临床试验并提供可靠的肿瘤学和毒性结局。
  • 共识和立场声明异质性大,全球公认的FT规划、技术和随访指南仍未确定。

核心结论

  • 全球公认的FT规划、技术和随访指南仍未确定。
  • 需要设计良好、长期随访且具有可靠临床和毒性终点的研究来改善对FT的理解并制定统一指南以简化管理和随访。

研究设计与样本

  • 对欧洲泌尿外科学会-欧洲核医学协会-欧洲放射肿瘤学会-欧洲泌尿生殖放射学会-国际泌尿病理学会-国际老年肿瘤学会及美国泌尿外科学会-美国放射肿瘤学会-泌尿肿瘤学会指南进行查询以获取FT推荐。
  • 检索PubMed和Ovid Medline以获取共识声明,仅纳入2015年以来发表的英文研究。
  • 对纳入文章的参考文献列表进行查询并手动检索研究。

主要发现

  • 结果显示缺乏FT的长期随机数据。
  • 国际泌尿外科指南强调需要更多高质量临床试验并提供可靠的肿瘤学和毒性结局。
  • 共识和立场声明异质性大。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To provide a summary and discussion of international guidelines, position statements and consensus statements in relation to focal therapy (FT) for prostate cancer (PCa). METHODS: The European Association of Urology-European Association of Nuclear Medicine-European Society for Radiotherapy and Oncology-European Society of Urogential Radiology-International Society of Urological Pathology-International Society of Geriatric Oncology and American Urological Association-American Society for Radiation Oncology-Society of Urologic Oncology guidelines were interrogated for recommendations for FT. PubMed and Ovid Medline were searched for consensus statements. Only studies in English since 2015 were included. Reference lists of the included articles were also interrogated and a manual search for studies was also performed. RESULTS: Our results showed a lack of long-term randomised data for FT. International Urological guidelines emphasised the need for more high-quality clinical trials with robust oncological and toxicity outcomes. Consensus and positions statements were heterogenous. CONCLUSION: A globally accepted guideline for FT planning, technique and follow-up are still yet to be determined. Well-designed studies with long-term follow-up and robust clinical and toxicity endpoints are needed to improve our understanding of FT and create uniform guidelines to streamline management and follow-up.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Ong S, Chen K, Grummet J, et al. Guidelines of guidelines: focal therapy for prostate cancer, is it time for consensus? BJU Int. 2022. PMID: 36083229. doi:10.1111/bju.15883

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。